BlackRock Amends ADMA Biologics Stake on Dec 31, 2023
Ticker: ADMA · Form: SC 13G/A · Filed: Jan 26, 2024 · CIK: 1368514
| Field | Detail |
|---|---|
| Company | Adma Biologics, Inc. (ADMA) |
| Form Type | SC 13G/A |
| Filed Date | Jan 26, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investment
TL;DR
**BlackRock updated its passive stake in ADMA Biologics as of year-end 2023.**
AI Summary
BlackRock Inc. filed an amended SC 13G/A on January 26, 2024, indicating a change in their ownership of ADMA Biologics Inc. common stock as of December 31, 2023. This filing, an amendment to a previous disclosure, shows BlackRock's updated passive investment position in the biological products company. This matters to investors because BlackRock is a major institutional investor, and changes in their holdings can signal their confidence (or lack thereof) in a company's future prospects, potentially influencing other investors.
Why It Matters
This filing updates BlackRock's passive ownership in ADMA Biologics, providing transparency into a major institutional investor's position, which can influence market sentiment.
Risk Assessment
Risk Level: low — This is a routine amendment by a passive institutional investor and does not indicate any immediate significant risk or opportunity.
Analyst Insight
Investors should note BlackRock's continued passive interest in ADMA Biologics, but this routine update doesn't suggest an immediate need for action. Further analysis of BlackRock's specific share count (not provided in this excerpt) would be needed to gauge the magnitude of any change.
Key Players & Entities
- BlackRock Inc. (company) — the institutional investor filing the SC 13G/A
- ADMA Biologics Inc. (company) — the subject company whose securities are being reported
- December 31, 2023 (date) — the date of the event requiring the filing
- January 26, 2024 (date) — the filing date of the SC 13G/A
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G filing, as indicated by 'FORM TYPE: SC 13G/A' and '(Amendment No: 1)' in the filing.
Who is the subject company of this filing?
The subject company is ADMA BIOLOGICS, INC., as stated under 'SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: ADMA BIOLOGICS, INC.' in the filing.
Who is the entity that filed this SC 13G/A?
The entity that filed this SC 13G/A is BlackRock Inc., as indicated under 'FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BlackRock Inc.' in the filing.
What was the date of the event that required this filing?
The date of the event which required this filing was December 31, 2023, as specified under '(Date of Event Which Requires Filing of this Statement) December 31, 2023'.
Under which rule was this Schedule 13G filed?
This Schedule 13G was filed under Rule 13d-1(b), as indicated by '[X] Rule 13d-1(b)' in the filing.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 26, 2024 regarding ADMA BIOLOGICS, INC. (ADMA).